Targeted approaches to t‐cell lymphoma

Abstract

The T‐cell lymphomas are a rare group of Non‐Hodgkin’s lymphomas derived from mature T‐lymphocytes. They are divided broadly into the Peripheral T‐cell lymphomas and the Cutaneous T‐cell lymphomas. Clinical outcomes vary widely but are generally unsatisfactory with current treatments. The development of an understanding of the various critical pathways in T‐cell lymphogenesis and subsequent identification of therapeutic targets has led to a rapid expansion of the previously underwhelming T‐cell lymphoma armament. This review aims to provide an up‐to-date overview of the current state of targeted therapies in the T‐cell lymphomas, including novel antibody‐based treatments, small molecule inhibitors and immune‐based therapies.